\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
There is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The Community for European Research and Innovation for Security (CERIS) is hosting a thematic workshop on European R&I solutions, as well as future capability needs, relevant for maritime situational awareness and security. The target audience includes practitioners, especially Coast Guards, but also innovators and policy makers on capabilities such as those related to search-and-rescue at sea, sea border surveillance, and other maritime security and safety functions.
Registration is free but mandatory. You can register here.
Draft agenda (also added as attachment)
09:30 - 10:00 Registration and Welcome Coffee
10:00 - 10:30 Welcome and opening remarks
10:30 - 12:30 Session I: Innovation for integrated maritime information management and sharing
12:30 - 13:45 Lunch break and poster session
13:45 - 15:00 Session II: Innovative technologies for maritime situational awareness
15:00 - 15:30 Coffee break
15:30 - 17:00 Session III: Panel on using today's innovation and preparing tomorrow
17:00 - 17:30 Conclusions
17:30 - 19:00 Networking reception
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
